CSL's Financial Results
Please click the link below to view our most recent and historic Full Year and Half Year Financial Results information.
More InformationSearch Results
378 results found-
Full-year (Aug 2017) and Share performance against CEO & Melbourne, Australia half-year (Feb 2018) results strategy, outlook, organisational Managing identity, generation/age, socio-economic Details of the directors, including their (includes webcast and activities and milestones Director status, religiousMale 70 beliefs,% professionalMale and XX% Male 44% qualifications and experience, together teleconference with questions educationalFemale background 30% as well asFemale global XX% Female 56% with details of their length of service, can and answers) and cultural experiences.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2018-full.pdf -
The myelin sheath, or the protective covering of the nerves, is damaged, which In October 2018, an expanded age indication for AFLURIA® may result in numbness or tingling, muscle weakness, fatigue QUADRIVALENT (influenza vaccine) for use in people six and other symptoms which worsen over time.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf -
Translational Medicine was opened in December 2018.
https://www.csl.com/-/media/csl/tax-transparency-reports/csl-limited-tax-transparency-report-2019.pdf -
pending test results after 2018), CSL Plasma donors related their Find out more at Find out more at a donation is made.
https://www.csl.com/-/media/csl/corporate-responsibility-reports/csl-limited-corporate-responsibility-report-2018.pdf -
Builds on company’s more than $3b U.S. investment since 2018 which created thousands of new jobs across 44 states
https://newsroom.csl.com/2025-11-18-CSL-to-invest-approximately-1-5b-in-U-S-to-manufacture-plasma-derived-therapies -
The Phase 3 trial, which enrolled its first patient in March of 2018, is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) to reduce the risk of cardiovascular death, myocardial infarction (MI) also known as a heart attack, and stroke in acute myocardial infarction (AMI) patients.
https://newsroom.csl.com/2020-11-05-CSL-Behring-Publishes-Design-for-First-Ever-Outcomes-Study-of-ApoA-I-to-Reduce-Risk-of-Cardiovascular-Events-in-Heart-Attack-Patients -
Hizentra was first approved by the U.S. FDA in March 2010 for the treatment of patients with PI and was approved in March 2018 for the treatment of adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
https://newsroom.csl.com/2024-01-16-Harris-Poll-Survey-Finds-People-Receiving-Treatment-for-CIDP-Are-Interested-in-Exploring-More-Convenient-Treatment-Options -
Hizentra was first approved by the U.S. FDA in March 2010 for the treatment of patients with PI and was approved in March 2018 for the treatment of adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to prevent relapse of neuromuscular disability and impairment.
https://newsroom.csl.com/2024-01-03-CSL-Behring-Announces-Availability-of-Hizentra-R-Immune-Globulin-Subcutaneous-Human-20-Liquid-10g-Prefilled-Syringe -
Dr Brian McNamee AO 14 February 2018 Independent, non-executive director and Chair
https://www.csl.com/-/media/csl/documents/csl-governance-docs/corporate-governance-statement-2025.pdf